deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT04402008

Study of Poziotinib in Japanese Patients With NSCLC

A Phase 1/2 Dose Finding Study of Poziotinib in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Spectrum Pharmaceuticals, Inc

Conditions NSCLC
Interventions Poziotinib Once Daily Dosing Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1 Poziotinib Twice Daily Dosing
Updated 13 times since 2020 Last updated: May 29, 2024 Started: Jun 23, 2020 Primary completion: Feb 15, 2023 Completion: Feb 15, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision, not related to safety.

Other terminated trials from Spectrum Pharmaceuticals, Inc

More terminations from Spectrum Pharmaceuticals, Inc

Other NSCLC trials with similar outcome

Browse all NSCLC trials

This PHASE1/PHASE2 trial investigates NSCLC and is currently terminated or withdrawn. Spectrum Pharmaceuticals, Inc leads this study, which shows 13 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Aug 2023 · 6 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Aug 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

  4. Feb 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Feb 2022 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Jun 2020 — Jul 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Spectrum Pharmaceuticals, Inc
Data source: Spectrum Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations